Conditions: Attention Deficit Hyperactivity Disorder
Keywords: ADHD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 338
Healthy volunteers: no

Brief summary:
For children and adolescents, how does SPD503 compare to placebo for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Detailed description:

Arms:
arm 1: None arm 2: Active Reference arm 3: None

Interventions: intervention 1: Extended-release Guanfacine Hydrochloride intervention 2: Atomoxetine Hydrochloride intervention 3: Placebo Comparator
Intervention descriptions: intervention 1: Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose. intervention 2: Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose intervention 3: Placebo

Protocol document: